Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, you can take a break from Mounjaro, but the clinical evidence is clear that stopping (even briefly) tends to reverse the metabolic changes driving your weight loss. Tirzepatide does not alter your biology permanently; once the medicine leaves your system, appetite and calorie regulation typically return towards their pre-treatment baseline. A prescriber should guide any planned pause, because the right approach depends on how long you have been on treatment, which dose you have reached, and why the break is being considered.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial (published in the New England Journal of Medicine) followed 2,539 adults over 72 weeks and found that average body-weight reductions reached around 20–21% at the 15 mg dose. The picture after the controlled treatment period ended is instructive: participants who discontinued the medicine regained a meaningful proportion of that weight within the following months. This mirrors what has been observed across the broader GLP-1 class, semaglutide extension data showed similar rebound patterns after discontinuation.
The reason is straightforward biology. Tirzepatide acts on GIP and GLP-1 receptors that regulate hunger signals, gastric emptying and energy balance. Remove the medicine and those receptors revert to their previous behaviour. There is no lasting reprogramming. A temporary break (whether a week or a full month) pauses the pharmacological effect; how quickly symptoms return depends on the individual, but the direction of travel is consistent across the trial evidence. This does not mean breaks are impossible or always wrong, but anyone considering one deserves an honest account of what the data shows.
The NHS medicines page for tirzepatide reinforces that this is a prescription medicine requiring ongoing clinical oversight, and any decision to pause should be made with that in mind rather than independently.
People ask about pausing Mounjaro for different reasons: a holiday abroad without reliable refrigeration, a surgical procedure, a period of illness, or concerns about cost. The duration matters clinically.
A one-week break (perhaps because a pen is delayed or you are travelling) is unlikely to cause dramatic weight regain in isolation, but it does mean a week without the appetite-suppressing effect. Some people notice hunger returning noticeably within days. If you take Mounjaro weekly and miss a single injection, the Patient Information Leaflet sets out the guidance for missed doses; your prescriber and the leaflet are the right sources for that specific situation, not general advice online.
A month-long break from Mounjaro is a more substantial pause, and our page on what a two-week break from Mounjaro means in practice is a useful starting point for understanding how even a shorter gap affects your progress. By the end of four weeks, tirzepatide will have cleared your system, appetite signals will have shifted, and any weight-loss progress may slow or reverse. There is also a practical implication for restarting: after a significant gap, retitration from a lower dose is typically recommended to manage gastrointestinal tolerability, your body needs time to readjust, just as it did at the start. People researching what taking a break from Mounjaro actually involves often underestimate how different restarting feels compared with continuing on a stable dose.
If cost is a factor in considering a break, it is worth reading about how Mounjaro is priced in the UK private market before making a decision based on incomplete information.
There are situations where pausing is genuinely the right clinical call, not just a lifestyle inconvenience. Planned surgery is one of them: NHS England's guidance on weight-management injections is explicit that your surgical and anaesthetic team must know you are taking a GLP-1 medicine, and a pre-operative pause is sometimes advised to reduce aspiration risk. A prescriber will tell you the appropriate timing.
Pregnancy, trying to conceive, or breastfeeding are absolute reasons to stop rather than pause, these are contraindications, not lifestyle considerations. Under-18s are not licensed to use tirzepatide at all. Severe or persistent gastrointestinal side effects that are affecting nutrition or hydration are another clinical reason to discuss dose reduction or a pause rather than simply continuing.
Understanding what a planned Mounjaro break involves and how to manage one safely looks very different from stopping Mounjaro suddenly, and it is worth understanding that distinction. If you are thinking about coming off treatment entirely, the considerations are broader still, what stopping Mounjaro suddenly involves covers that specific question. The short version: abrupt discontinuation carries no dangerous withdrawal syndrome, but the return of appetite can be rapid and disorienting if you have been on a higher dose for some time.
Storage constraints do come up as a practical prompt for pauses. If you are going somewhere without reliable refrigeration (a long camping trip, for example, or a flight to a destination where you are unsure of storage conditions) it is worth planning ahead rather than letting the pen sit outside the fridge for longer than the SmPC permits. The leaflet gives the specific room-temperature window; do not rely on a general estimate online.
The clearest practical advice is: do not just stop. Contact your prescribing team before the break, explain the reason, and get guidance on whether to hold the next dose, whether to retitrate on return, and what to watch for in the interim. At nume, a real clinician reviews your situation, the same principle applies to mid-treatment decisions as it does to the original consultation.
People who have been on treatment long enough to understand their own patterns (how their appetite behaves at a given dose, which foods remain easy to eat, how their weight has tracked) tend to navigate breaks more confidently. Those earlier in their journey may find the shift in appetite more unsettling, and reading about whether you can have a break from Mounjaro and what to expect can help set realistic expectations before you make any decision. Both are valid; both are clinical conversations worth having before the break rather than after.
If you are weighing up whether treatment is right for you longer term, our weight-loss treatment overview sets out the options clearly. And if you have questions that do not fit a standard FAQ, our general FAQs or the clinical team are there to help. Speak to our prescribers before making any change to your Mounjaro schedule, a five-minute conversation now tends to save a lot of second-guessing later.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.